Infliximab as salvage therapy in paediatric intestinal transplant with steroid- and thymoglobulin-resistant late acute rejection

J Pediatr Gastroenterol Nutr. 2012 Apr;54(4):565-7. doi: 10.1097/MPG.0b013e3182293d73.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antilymphocyte Serum / pharmacology
  • Basiliximab
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Drug Resistance
  • Female
  • Humans
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / pharmacology
  • Infliximab
  • Intestines / pathology
  • Intestines / transplantation*
  • Male
  • Recombinant Fusion Proteins / pharmacology
  • Salvage Therapy*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab
  • Infliximab
  • thymoglobulin